Cyclophosphamide 'offers no survival benefit' with fibrosis flares

Adding the agent to high-dose glucocorticoids for flares of idiopathic pulmonary fibrosis might even be harmful, study suggests

Patients with an acute exacerbation of idiopathic pulmonary fibrosis (IPF) treated with high-dose glucocorticoids showed a trend towards increased mortality with added pulsed cyclophosphamide, researchers have found.

The French study findings provide evidence against the use of the IV therapy in such patients, the authors say.

The phase III Cyclophosphamide added to Glucocorticoids in acute Exacerbation of Idiopathic Pulmonary Fibrosis (EXAFIP) trial funded by Roche, was carried out in